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httpense.Abstract Background: Pulmonary tuberculosis is a major cause of morbidity and mortality World
Wide, resulting in the greatest number of deaths due to any other single infectious agent. Drug resis-
tance threatens global tuberculosis control efforts. Multi drug resistance means drug resistance to at
least rifampicin and isoniazid.
Methods: One hundred and nineteen sputum and culture positive patients underwent drug sus-
ceptibility to the ﬁrst line drugs (Isoniazid, Rifampicin, Streptomycin and Ethambutol). 79/119
patients in addition underwent drug susceptibility to Pyrizinamide, Oﬂoxacin, Amikacin and Lev-
oﬂoxacin.
Results: The susceptibility test shows that 35/119 patients (29.4%) were sensitive to all the tested
drugs. 84/119 of the included patients (70.6%) showed drug resistance to at least one of the ﬁrst line
drugs by different patterns. 29/119 patients were diagnosed as MDR cases with a percent of 31%
(resistant to both INH and Rifampcin).
Conclusion: This study shows increase incidence of resistance to ﬁrst line drugs as well as
increase incidence of MDR.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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om (S. Elawady).
e Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculos
://dx.doi.org/10.1016/j.ejcdt.2012.0Introduction
Tuberculosis remains an important public health problem in
Egypt. It is estimated that 17,200 people develop TB every year.
Although Egypt has an intermediate level of incidence and
mortality (24 and 3 per 100,000 populations respectively), this
burden is still a matter of concern, particularly in light of the
fact that 66% of TB cases occur among the socially and
economically productive age groups of 15–54 years. The latestis. Production and hosting by Elsevier B.V.
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344 K. Aid Sobhy et al.surveillance of our national data was obtained in 2006 revealed
that the prevalence rate of TB is 35/100,000 of the population
and the estimated incidence rate per 100,000 of the population:
For all types of TB is 24 (meaning 17,200 estimated numbers of
cases) and is 11 for sputum positive cases (meaning 7850 esti-
mated positive cases) National TB control program 2007 [1].
Multi-drug resistant TB is 2.2% of the new cases and
38.4% among re-treatment cases (according to a national sur-
vey in 2002).
The aim of this prospective study was to review the current
incidence and the pattern of drug resistance for TB patients.
Patients, methods
This study was conducted on 144 patients. They were inpa-
tients of Chest department, Kasr El Aini University hospital,
El Giza Chest hospital, El Abassia Chest hospital in the period
from November 2009 to April 2010.
All these patients were presenting by smear positive pul-
monary tuberculosis, either newly diagnosed cases, cases with
treatment failure, defaulters or relapsed cases.
Deﬁnitions (WHO, 2010) [2]
A ‘new case’ is deﬁned as a newly registered episode of TB
in a patient who, in response to direct questioning denies hav-
ing had any prior anti-tuberculosis treatment.
A ‘previously treated case’ is deﬁned as a newly registered
episode of TB in a patient who, in response to direct question-
ing admits having been treated for TB for one month or more
(Chemoprophylaxis should not be considered treatment for
TB).
Previously treated cases (also referred to as ‘‘retreatment
cases’’) are a heterogeneous group composed of several
subcategories:
‘‘Relapse’’ – a patient whose most recent treatment out-
come was ‘‘cured’’ or ‘‘treatment completed’’, and who is sub-
sequently diagnosed with bacteriologically positive TB by
sputum smear or culture.
‘‘Treatment failure’’ – a patient who is started on a re-treat-
ment regimen after having failed previous treatment for TB.
Failure is deﬁned as sputum smear positive at ﬁve months or
later during treatment.
‘‘Defaulter’’ – a patient who returns to treatment, bacterio-
logically positive by sputum smear microscopy or culture, fol-
lowing interruption of treatment for two or more consecutive
months.
Inclusion criteria
In our study, every case presenting by clinical and radiological
ﬁndings suggestive of pulmonary tuberculosis and sputum po-
sitive for mycobacterial tuberculosis by Zeil Neelsen technique,
was collected, whether a new fresh case or previously treated
case, regardless his age, sex, occupation, other co-morbid con-
ditions, receiving anti-mycobacterial treatment or not.
Patients were subjected to full history taking, clinical exam-
ination, evaluation of chest radiography, laboratory study,
Sputum examination by Ziel Neelsen technique, culture using
Lo¨wenstein–Jensen media Heifets [3] and drug susceptibility
testing using the proportion method WHO [4].
Principle of proportion method
Only one concentration per drug was used. The concentrations
are as follows: Isoniazid 0.2 lg/ml Streptomycin 4 lg/mlRifampicin 40 lg/ml Ethambutol 2 lg/ml Pyrizinamide
30 lg/ml (PH 5.5). Oﬂoxacin 2 lg/ml Levoﬂoxacin 2 lg/ml
Amikacin 1 lg/ml. (All the drugs and chemicals were procured
from Sigma, USA).
The bacterial suspension from the primary culture was pre-
pared and the opacity of this bacterial suspension was then ad-
justed by the addition of distilled water to a standard
suspension containing 1 mg/ml of tubercle bacilli (or BCG).
Two slopes of medium without drug and two with drug were
inoculated with 0.1 ml of the bacteria suspension (two chosen
dilutions). The results were read for the ﬁrst time on the 28th
day by counting the colonies grown on the different slants,
then the calculation of the proportion of resistant bacilli by
comparing counts on drug free and drug containing L–J med-
ium. The proportions are reported as percentages. Below a cer-
tain value – the critical proportion – the strain is classiﬁed as
sensitive; above that value, it is classiﬁed as resistant. If the re-
sult of the reading made on the 28th day is ‘‘resistant’’, no fur-
ther reading of the test for that drug is required, the strain is
classiﬁed as resistant. If the result at the 28th day is ‘‘sensi-
tive’’, a second reading was made on the 42nd day: this pro-
vides the deﬁnitive result WHO [4]. Any strain with 1% (the
critical proportion) of bacilli resistant to any of the four
drugs–rifampicin, isoniazid, ethambutol, and streptomycin is
classiﬁed as resistant to that drug
 Evaluation of the chest radiography of each case regarding
the extent of the lesion, the bilaterality, the presence of cav-
itation and its size according to National Tuberculosis
Association of the USA in 1961.
 Minimal: lesions are of slight to moderate density, no cav-
itary lesions and involve a small part of one or both lungs
but the total extent regardless of distribution should not
exceed volume present above the second chondrosternal
junction of one side.
 Moderately advanced lesions: total extent should not
exceed the following:
a- Disseminated lesions of slight to moderate density which
may extend throughout the total volume of one lung.
b- Dense and conﬂuent lesions which are limited in extent
to one third the volume of one lung.
c- Total diameter of cavitation if present is less than 4 cm.
 Far advanced lesions: are more extensive than moderately
advanced lesions.Results
A total of 144 sputum positive cases were recruited initially.
However 25 patients were excluded as their culture for tuber-
culosis was negative. All cultures were Mycobacterium tuber-
culosis species. Patients proﬁle is included in Table 1.
Radiological extent of TB lesions include 62 patients
(52.1%) as minimal lesions, 53 patients (44.5%) as moderately
advanced and 4 patients as far advanced lesions (3.4%).
Drug susceptibility test showed that only 35 patients
(29.4%) were sensitive to all the tested drugs. 84 of the in-
cluded patients (70.6%) showed drug resistance to at least
one of the ﬁrst line drugs by different patterns (Tables 2–5).
29 patients (31%) were diagnosed as multi-drug resistance.
There were 23 males (79.3%) and 6 females (20.7%) with age
ranged 20–60 years with a mean of 37.8 ± 10.5. Most of them
Table 1 Patients proﬁle.
Variables No. of patients 119
Age 36.2 ± 12.4 (12–81 years)
Sex (M:F) 92:27
Residence
(a) Rural area 84 (70.6%)
(b) Urban area 35 (29.4%)
Occupation
(a) Manual workers 57 (47.8%)
(b) Non manual workers 62 (52.1%)
Smoking habit 82/119 (67.2%)
(a) Cigarette 47 (39.5%)
(b) Shisha 35 (29.4%)
Alcohol 12 (10.1%)
Drug addiction 25 (21%)
Co-morbidity
(a) Diabetes mellitus 19 (16%)
(b) Hypertension 14 (11.7%)
(c) Ischemic heart disease 3 (2.5%)
(d) Chronic renal failure 2 (1.6%).
(e) Chronic liver disease 2 (1.6%)
Previous anti-TB drug
(a) New cases 65 (54.6%)
(b) Relapse 11 (9.2%)
(c) Treatment failure 31 (26%)
(d) Defaulter 12 (10.1%)
Table 2 Prevalence of drug resistance to the ﬁrst line drugs in
New and Retreated cases.
Drug Resistance New cases % Retreated cases %
INH 12.3 50
Rifampicin 20 59.9
Streptomycin 18.5 48.2
Ethambutol 12.3 31
Pyrizinamide
(tested in 79 cases only)
31.3 44
MDR 13.8 38.8
Table 3 Prevalence of 2nd line drug resistance in new and
retreated cases.
Drug resistance New cases % Retreated cases %
Oﬂoxacin 29 25
Amikacin 15 24
Levoﬂoxacin 10.7 15
Table 4 Pattern of drug resistance to the ﬁrst line drugs in the
included patients.
Total Percent %
Totally tested 119 100
Fully sensitive 35 29.4
MDR 29 31
Any resistance 84 70.6
Resistant to H 6 5
R 7 5.8
S 6 5
E 2 1.7
Z 18 15
HR 6 5
RS 4 3.4
RE 1 0.8
RZ 3 2.5
SE 1 0.8
SZ 1 0.8
EZ 4 3.4
HRE 2 1.7
HRS 5 4.2
HRZ 1 0.8
REZ 1 0.8
RSZ 1 0.8
HRSZ 14 11.8
HRESZ 1 0.8
(H: INH R: Rifampcin S: Streptomycin Z: Pyrizinamide E:
Ethambutol).
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urban area, 16/29 (55.2%) were manual workers and 13
(44.8%) were non-manual workers, 22/29 (75.8%) patients
were smokers (15/29 patients (48.3%) were cigarette smokers
and 7/29 patients (20.7%) were shisha smokers). 3/29 patients
(10.3%) were diabetics. There was no statistical difference be-
tween MDR patients and non MDR patients in patient proﬁle.
Drug susceptibility testing amongMDR patients is shown in
Table 6. MDR patients show a moderate invasive radiologicallesion that was statistically signiﬁcant (Table 7). 9/29 patients
(31%) were diagnosed as new cases, history of anti-TB treat-
ment in MDR is shown in Table 8.
Discussion
Our study was conducted on 119 patients presenting by smear
positive pulmonary tuberculosis and proved to be culture po-
sitive for tuberculosis using LJ medium, searching for the prev-
alence of anti-mycobacterial drug resistance and the pattern of
drug resistance. The drug susceptibility testing was carried also
on Qunilones and Aminoglycosides (presented by Oﬂoxacin,
Levoﬂoxacin, and Amikacin), to study their efﬁcacy on the
drug resistant strains and to determine the frequency of the
emergence of ﬂuoroquinolone-resistant strains. Drug suscepti-
bility testing was done using the proportion method. The
proportion method is the most commonly used method world-
wide. It allows the precise determination of the proportion of
resistant mutants to a certain drug Heifets [3].
It was noticed that 17.4% (25/144) of the initially selected
patients with positive sputum for AFB direct smear, yield neg-
ative culture for pulmonary tuberculosis. This might be due to
the presence of dead non-viable bacilli in the sputum of the
ongoing treated patients. This percent was less than what
was found in Paramasivan et al. [5] study, where more than
half of the smear positive cases included were culture negative.
And lower than the results of Barbara et al. [6], where only 2%
of the smear positive cases showed negative culture for
tuberculosis.
In this study, the mean age of the included patients was
37.8 years which is comparable to Hossam [7] who reported
that the mean age group was 32.6 years. Mohamed et al. [8]
Table 5 Relation of drug-resistance to the type of the patient (according to the history of previous anti-TB drugs).
Total Percent from
total resistance %
Mono-resistance % Resistance to
two drugs %
Resistance to
3 drugs %
Resistance to
4 drugs %
P Value
New case 44 52.4 56.8 27.3 4.5 11.4 <0.005
Retreated cases 40 47.6 32.5 20 25 22.5 >0.005
Total resistant cases 84 100
Table 6 Pattern of drug resistance in MDR patients.
Drug resistant Percent %
INH 100
Rifampcin 100
Streptomycin 69
Ethambutol 58
Pyrizinamide (tested in 11 patients only) 18 (no. = 2/11)
Oﬂoxacin (tested in 11 patients only) 18 (no. = 2/11)
Amikacin (tested in 11 patients only) 45 (no. = 5/11)
Levoﬂoxacin (tested in 11 patients only) 18 (no. = 2/11)
Table 8 History of anti-TB treatment in MDR patients.
Variables MDR patients Non MDR patients P Value
Number Percent % Number Percent %
New Case 9 31 56 62.2 =0.05
Treatment
failure
14 48.3 13 14.4 <0.05
Relapse 3 10.3 8 8.9 >0.05
Defaulter 3 10.3 9 10 >0.05
Total 29 100 90 100
346 K. Aid Sobhy et al.stated that the mean age group was 34.9 years in newly diag-
nosed patients and the mean age to retreated cases was
36.5 years. This may be due to increase of exposure to infection
in active age group and the effect of physical and mental stress.
The study included 92 males (77.3%) and 27 females
(22.7%), also in MDR patients there were 79.3% males and
20.7% females with no signiﬁcant statistical difference in the
prevalence of drug resistant tuberculosis as regarding the sex.
This study was comparable to Hossam [7] who reported that
the percentage of tuberculous males was 76% and that of fe-
males was 24%. Assad [9] reported that 75.9% of tuberculous
patients in his study were males and 24.1% were females. This
also coincides with the epidemiological picture of tuberculosis
where males are more exposed to infection in the community
than females because of occupational and mental stress or
other social factors which prevent females from seeking medi-
cal advice, which may cause a false lowering of the incidence
rate in females.
In this study, there was no signiﬁcant statistical difference
in the incidence of pulmonary tuberculosis and drug resistant
tuberculosis as regards the occupation, where 48% were man-
ual workers and 52% were non-manual workers. This coin-
cides with Abd-El Fatah [10] where 56% were manual
workers and 44% were non-manual workers. This current
study did not coincide with Mohamed et al. [8] and Fawzy et
al. [11] who reported that the manual workers were more liable
to MDR TB than the non-manual workers.
As regarding the associated special habits, its showed that
39.5% of the included patients were cigarette smokers and
28.6% of them were shisha smokers, which is high comparableTable 7 Radiological extent of the lesions in the MDR patients.
Variables Minimal Moderately inv
Number Percent % Number
MDR 11 17.7 17
Non-MDR 51 82.3 36
Total 62 100 53to the prevalence of cigarette and shisha smokers among the
Egyptian population, with a signiﬁcant statistical difference.
However, there was no signiﬁcant statistical difference as
regards smoking or type of smoking (cigarettes or shisha) in
the prevalence of drug resistant tuberculosis. This study coin-
cides with Khaled et al. [12], who found that 31% of the pa-
tients were cigarette smokers and 29% were shisha smokers,
with a signiﬁcant statistical difference. This also coincides with
Abd El Fatah [10] who reported that 29.2% of the included pa-
tients were cigarette smokers. But this study did not coincide
with Fawzy et al. [11] who reported that there was no statisti-
cally difference as regards smoking among TB patients. Smok-
ing increases the risk for pulmonary tuberculosis by the effect
of smoking on the pulmonary host defenses. Chronic exposure
to cigarette smoke causes alteration in the cellular and humor-
al immunity.
The most common co morbidity observed in this study was
diabetes mellitus. It was found that 16% of the total included
patients were diabetics, (higher than the prevalence of diabetes
in the Egyptian population (11%) as stated by the WHO 2008,
with a signiﬁcant statistical difference). Also there was no sig-
niﬁcant statistical difference between the diabetics and non-
diabetics MDR TB patients. This means that diabetes is a risk
factor for Pulmonary Tuberculosis rather than Drug resistant
Tuberculosis. Our study was in disagreement with Bashar et al.
[13] who showed that MDR tuberculosis was signiﬁcantly
higher in patients with coexisting diabetes mellitus where
36% of the patients with diabetes and tuberculosis had multi-
drug-resistant tuberculosis (MDR-TB) compared to only 10%
in the control group (p< 0.01). In Elizabeth et al. [14] diabetesasive Far advanced P Value
Percent % Number Percent %
32.1 1 25 <0.005
67.9 3 75
100 4 100
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the incidence of DM was 8% among the MDR patients com-
pared to 10% among the control group.
It was noticed that the highest proportion of the pulmonary
tuberculous patients presented by minimal lesions (radiologi-
cally), least presentation was the far advanced lesions, this
means better and earlier diagnosis of pulmonary tuberculosis.
These ﬁndings coincide with Fawzy et al. [11], where minimal
lesions were the most common presentation among his pa-
tients. But did not coincide with Abdelazim et al. [15] who
revealed that 58% of patients had far advanced lesion in chest
X-ray followed by minimal lesion in chest X-ray 26%.
Our study showed that only 35 cases (29.4%) have shown
full sensitivity for the ﬁrst line drugs. Eighty four cases
(70.6%) have shown resistance to any of the ﬁrst line drugs
in different patterns with 31% MDR cases. Our ﬁndings did
not coincide with the global prevalence of MDR 2008
(3.8%), and also did not coincide with the national surveil-
lance done in Egypt 2001, which included 1102 cases, where
67.3% of cases were sensitive to all drugs, 32.7% with
resistance to any of the ﬁrst line drugs. But coincides with
El-Gazzar et al. [16] study which showed a high MDR preva-
lence among the studied cases (51.2%).
In India, Paramasivan et al. [5] was carried out on 384 pa-
tients, the isolates from 312 (81.2%) patients were fully suscep-
tible to all the drugs tested, while isolates from 72 patients had
resistance to one or more drugs. MDR cases represented 3.4%.
In Iran, Majid et al. [17] study was carried out on 43 patients
ﬁnding a very high prevalence of MDR cases 88%. In Saudi
Arabia, Rupak et al. [18] study was carried out on 515 patients
and reported that 15.5% have shown resistance to any of the
ﬁrst line drugs and 2.8% were MDR cases.
Our ﬁndings coincide with Subba et al. [19], where 35.55%
were sensitive to all the four drugs whereas the remaining was
resistant to two or more drugs and 23% were MDR cases.
Our study showed the following pattern of drug resistance:
INH resistance was 12.3% among new cases, 50% among the
retreated cases, Rifampcin 20% in new cases, 59.9% in re-
treated cases, Streptomycin 18.5% in new cases, 48.2% in re-
treated cases, Ethambutol 12.3% in new cases, 31% in
retreated cases, Pyrizinamide 31.3% in new cases, 41% in re-
treated cases, Oﬂoxacin 29% in new cases, 25% in retreated
cases, Amikacin 15% in new cases, 24% in retreated cases,
and Levoﬂoxacin 10.7% in new cases, 15% in retreated cases.
These ﬁndings were identical to the results of the national
Egyptian survey carried out and published in 2001, as regards
Streptomycin resistance which was 18% in new cases, 48% in
retreated cases, near to the INH resistance results which was
9.3% in new cases, 43% in retreated cases. Far from Rifamp-
cin resistance results which showed 3.6% in new cases, 46.3%
in retreated cases and Ethambutol showed 2.1% in new cases,
25.8% in retreated cases. In Emirates, Mansour et al. [20]
showed also the following high pattern of drug resistance
among the newly diagnosed cases: resistance to Rifampcin
was 37%, INH 30%, Streptomycin 26%, Ethambutol 19%.
In Saudia Arabia Rupak et al. [18], had showed less prevalence
of drug resistance among the new cases where resistance to
streptomycin was (9.7%), rifampicin (9.5%) isoniazid (4.3%)
and ethambutol (0.2%). In Lebanon, George et al. [21] study
showed INH resistance 12% in new cases 63% in retreated
cases, Rifampcin 3% in new cases 59% in retreated cases,Streptomycin 12% in new cases 44% in retreated cases, Eth-
ambutol 3% in new cases, 44% in retreated case
It was noticed that the most common drug resistant pattern
among the newly diagnosed cases was mono-resistance with a
signiﬁcant statistical difference. Our study was comparable to
Dursun et al. [22], where 60% of drug resistance among the
new cases was mono-resistance.
It was found that 31% of MDR cases were new cases while
48% were treatment failure. Relapse and defaulters represent
10.3% each. Said et al. [23] found that 44% of MDR TB pa-
tients were newly diagnosed cases (fresh Cases). Also Kamal
[24], who found that a high percent of the MDR cases
(46.2%) were new cases. Abd El Fatah [10] who found that
among the MDR patients in his study treatment failure repre-
sents 61.1%, defaulters 33.6%, but new cases only 4.4%.In conclusion
Drug resistance tuberculosis is a threat to the national tubercu-
losis control program. We recommend that culture and sensi-
tivity should be done to all new cases of TB.References
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